US policymakers debating restrictions on China's biotech sector may be influenced by competition in industries like semiconductors and electric vehicles. This approach is flawed because it fails to recognize that the life sciences industry is fundamentally different, with unique dynamics in innovation, IP, and global collaboration that don't map directly from other technology sectors.

A disconnect exists between the public rhetoric of U.S. pharma leaders, who frame China's growing biotech sector as a threat, and their corporate actions. These same companies are investing heavily in Chinese R&D and manufacturing, revealing a dual strategy of public caution and private commitment to integrating China into the global biopharma ecosystem.

Current US legislative focus on restricting capital and IP flow to China's biotech sector may be misdirected. The more pressing national security vulnerability is the heavy US reliance on China for the physical supply chain of drug manufacturing, including inputs and finished products, which remains largely unaddressed.

To compete with China's rapid 'me-better' development, U.S. innovators should proactively partner with Chinese firms to create improved versions of their own drugs. This self-cannibalization strategy is necessary to stay ahead before competitors do it for them.

Driven by significant government investment, China is rapidly becoming a leader in biotech R&D, licensing, and outsourcing. This shift is a top-of-mind concern for US biotech and pharma executives, with China now involved in a majority of top R&D licensing deals.

The true competitive advantage of China's biotech sector is its integrated architecture that rapidly moves scientific insights into early human clinical signals. This creates faster iteration and learning loops, a more profound threat than simple speed or cost advantages.

The narrative of China's biopharma industry as an imminent threat to U.S. dominance is often exaggerated. In reality, Chinese biotechs are fundamentally dependent on foreign markets to sustain innovation, as their domestic market is insufficient. This reliance forces collaboration, making them partners as much as competitors and limiting their ability to act independently.

According to investor Joe Edelman, China's main strength is developing new molecules. This means US and European firms will increasingly in-license drugs from China, creating fierce competition for the small US biotechs that traditionally filled this pipeline role for larger pharmaceutical companies.

John Crowley, CEO of Bio, argues the best strategy for US biotech dominance is not protectionism. Instead, the focus should be on improving the US's own competitive advantages, like streamlining regulations and lowering innovation costs, to maintain its lead rather than trying to stifle Chinese research.